Newtown biopharm firm could reap $50M from Chinese licensing deal

Onconova Therapeutics Inc. could receive more than $50 million under a licensing deal it signed Monday for its lead experimental cancer therapy. HanX Biopharmaceuticals acquired the rights in Greater China to rigosertib, a new drug candidate Bucks County-based Onconova is developing initially as a treatment for patients at higher risks for developing myelodysplastic syndromes of MDA. MDS is a type of cancer that can occur when the blood-fo rming cells in bone marrow become abnormal. Under the…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

In conclusion, we showed hypermethylation of CpGs as a novel mechanism of action for DNMTi agents and identified 638 hypermethylated molecular targets (CpGs) common to decitabine and azacytidine therapy. These novel results suggest that hypermethylation of CpGs should be considered when predicting the DNMTi responses and side effects in cancer patients. Introduction DNA methyltransferase inhibitors (DNMTi) are widely used as chemical tools for hypomethylating the genome, with an aim to understand the role of DNA methylation in multiple processes (e.g., X-chromosome inactivation and DNA imprinting) and as an anti-ca...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Markus Hartl* and Rainer Schneider Center of Molecular Biosciences (CMBI), Institute of Biochemistry, University of Innsbruck, Innsbruck, Austria The neuronal proteins GAP43 (neuromodulin), MARCKS, and BASP1 are highly expressed in the growth cones of nerve cells where they are involved in signal transmission and cytoskeleton organization. Although their primary structures are unrelated, these signaling proteins share several structural properties like fatty acid modification, and the presence of cationic effector domains. GAP43, MARCKS, and BASP1 bind to cell membrane phospholipids, a process reversibly regulate...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: These finding suggest that Poly-ICLC could be safely used for inducing transient innate immune responses in treated HIV+ subjects indicating promise as an adjuvant for HIV therapeutic vaccines. Trial Registration: www.ClinicalTrials.gov, identifier: NCT02071095. Introduction Innate immune dysregulation during HIV infection hinders the formation of anti-HIV adaptive immunity (1–6) resulting in rampant viral dissemination and progression to AIDS. Adherence to combination anti-retroviral therapy (cART) regimens controls viremia, restores CD4+T cell counts and reverses immune dysfunction to a larg ext...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionsMany patients with MDS, AA, and PNH report severe fatigue. The helpfulness of fatigue management strategies may impact patients ’ continued use; whether these strategies are beneficial and decrease fatigue levels needs more study.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
This study showed that potential vicious cycles underlying ARDs are quite diverse and unique, triggered by diverse and unique factors that do not usually progress with age, thus casting doubts on the possibility of discovering the single molecular cause of aging and developing the single anti-aging pill. Rather, each disease appears to require an individual approach. However, it still cannot be excluded that some or all of these cycles are triggered by fundamental processes of aging, such as chronic inflammation or accumulation of senescent cells. Nevertheless, experimental data showing clear cause and effect relationships...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/AML) are rare but well-recognized complications of cancer therapy. Allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning (MAC) remains the mainstay of treatment but is associated with a high incidence of non-relapse mortality (NRM). Reduced intensity conditioning (RIC) may reduce NRM in these heavily pre-treated patients. The primary objective of this study was to compare outcomes following RIC and MAC regimens in patients receiving an allogeneic HCT.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 17 Source Type: research
ConclusionsMany patients with MDS, AA, and PNH report severe fatigue. The helpfulness of fatigue management strategies may impact patients ’ continued use; whether these strategies are beneficial and decrease fatigue levels needs more study.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
We examined the effects of different variables (see methods) on the probability to 1) survive long enough to receive HCT and 2) to receive HCT if such survival occurred.Methods: We enrolled 695 pts (Table 1). Data on demographics, AML status, cytogenetic risks per European Leukemia Network (ELN), and response; age; comorbidities per the HCT-comorbidity index (CI); function including instrumental activities of daily living (IADL) and activities of daily living (ADL); frailty including walk test; geriatric assessment (GA) including cognition; Karnofsky performance status (KPS); QOL including the Functional Assessment of Canc...
Source: Blood - Category: Hematology Authors: Tags: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I Source Type: research
Conclusions:In population-based analyses, the survival of t-MDS remains dismal with outcomes particularly worse with advancing age and following primary cancer sites that are typically managed with combined modality regimens including chemotherapy and radiation. Findings from the real-world population level data such as this should be used as outcome benchmarks in clinical trials to assess therapeutic effectiveness of experimental treatments.DisclosuresGerds: Apexx Oncology: Consultancy; Celgene: Consultancy; Incyte: Consultancy; CTI Biopharma: Consultancy. Nazha: MEI: Consultancy. Carraway: Jazz: Speakers Bureau; FibroGen...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions: Outcomes in Myeloid Malignancies and Allogeneic Stem Cell Transplant Source Type: research
Background: Consensus guidelines recommend anticoagulation for 3 months in patients with upper extremity catheter-related thrombosis (CRT); however, recommendations are primarily extrapolated from data on provoked lower extremity thrombosis. Many patients with hematologic malignancy are treated with shorter durations of anticoagulation due to thrombocytopenia and other bleeding concerns. It is not known if duration of anticoagulation in patients with hematologic malignancy patients and CRT predicts risk of recurrence or hemorrhage.Methods: We performed a multicenter retrospective cohort study at five institutions through t...
Source: Blood - Category: Hematology Authors: Tags: 332. Antithrombotic Therapy: Poster I Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | China Health | Health Management | Myelodysplastic Syndrome